Skip to content

12-Week, Randomized, Double-Blinded, placebo-controlled Human Application Trial to Evaluate the Effectiveness and Safety of Broccoli NMN on Skin Wrinkle Improvement and Moisturization

12-Week, Randomized, Double-Blinded, placebo-controlled Human Application Trial to Evaluate the Effectiveness and Safety of Broccoli NMN on Skin Wrinkle Improvement and Moisturization

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0010297
Enrollment
80
Registered
2025-03-14
Start date
2025-01-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Eat test food (150 mg/day as broccoli NMN) or control food once a day, once a capsule with water (12 weeks)

Sponsors

Daedeok Pharma
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) A person who is 35 years of age or older and 65 years of age or younger 2) In the visual evaluation, those with both left and right eye corner wrinkles are Grade 3 or higher 3) Those who have less than 49 AU of skin moisture in the left and right cheeks (the right angle crossing between the tail of the eye and the tip of the nose) in Visitation 1 and Visitation 2 4) A person who agrees to participate in this human body application test before the human body application test begins and prepares a written consent form.

Exclusion criteria

Exclusion criteria: 1) Severe cardiovascular system, immune system, respiratory system, gastrointestinal/hepatic and biliary system, kidney and urinary system, nervous system, mental, infectious disease, and malignant tumor can participate in the test at the discretion of the tester. 2) Persons with mental illness such as schizophrenia, depression, drug addiction, alcohol use and induction disorder, etc 3) A person who has skin diseases such as atopic dermatitis, psoriasis, etc 4) A person who has skin abnormalities such as spots, acne, erythema, capillary dilatation, etc. at the test site 5) A person who has undergone Botox, filler, etc. treatment on his/her face within six months as of visit 1 6) A person who has used steroid-containing skin external agents on his/her face or has taken oral retinoid drugs or steroids within 3 months as of visit 1 7) A person who has received the following medication and procedures within one month (30 days) as of visit 1 ? Obesity drugs (fat absorption inhibitors, appetite inhibitors, etc.) ? psychiatric drugs such as depression and schizophrenia ? contraceptives or hormones ? diuretics, immunosuppressants ? Facial laser treatment, skin peeling, other skin care, etc ? Acne treatments (Cleartin, Creosinty, etc.) 8) A person who has used functional cosmetics (retinoids, AHA, etc.) for wrinkle improvement, high moisture and elasticity cosmetics, or skincare devices (LED masks, ion boosters, etc.) within two weeks as of visit 1 9) A person who has taken the following drugs and foods within two weeks on the basis of visiting 1 ? Medicines and health functional foods for improving skin wrinkles and moisturizing effects (anti-oxidants, hyaluronic acid, collagen, almacroids, vitamins A, E, C-containing medicines, and health functional foods) ? Broccoli-related health functional foods and health juices ? Health functional foods related to niacin (nicotinic acid) 10) Excessive smokers (20 or more per day) 11) A person who has a history of alcohol abuse or is chronically consuming alcohol* * Drinking alcohol equivalent to an average of 40 g (280 g/week) per day for men and an average of 20 g/week for women (140 g/week) per day for women 12) A person who has no outdoor activities at all, and who has plans for overseas business trips and overseas trips during the human body application test period 13) A person whose AST (GOT) or ALT (GPT) is more than three times the upper limit of the agency's normal limit 14) Those with a TSH of 0.1 µIU/mL or more or 10 µIU/mL or more 15) A person with an eGFR of less than 60 mL/min/1.73 m2 16) Uncontrolled diabetics (HbA1c exceeds 7.0%) 17) Uncontrolled hypertension patients (systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg, and measurement criteria after stabilizing for 10 minutes) 18) A person who is pregnant or is lactating or has a pregnancy plan during the main human body application test period 19) A person who has participated in other interventional clinical trials (including human-applied trials) within three months of the visit 1 or who plans to participate in other interventional clinical trials (including human-applied trials) during this human-applied trial period 20) A person who is sensitive to or allergic to the ingredients of the food (test or control food) for this human application test 21) A person who judges that the tester is inappropriate for other reasons

Design outcomes

Primary

MeasureTime frame
Skin wrinkles (eye evaluation,Mark-vu);Skin wrinkles(PRIMOS CR);skin moisture content

Secondary

MeasureTime frame
Percutaneous moisture loss;skin elasticity;skin texture;Skin brightness;Evaluation of the improvement of the human body test testers;Evaluation of Improvement of Subjects for Human Application Examination

Countries

Korea, Republic of

Contacts

Public Contactju hee Lee

Yonsei University Health System, Severance Hospital

jamunprof@gmail.com+82-70-4139-0796

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026